A group of researcher published an article in “Nature” reporting the discovery of a new cell wall inhibitor, teixobactin, from a screen of uncultured bacteria grown in diffusion chambers in situ using “ iChip” technology.
This powerful new antibiotic is reported to kill an array of drug-resistant bacteria in experimental infections in mice.It is a first new class of antibiotics discovered in decades
Many scientists think that this is a much-needed breakthrough that could lead to a whole new class of disease-fighting treatments which has excited scientists, doctors and the public all over the world.
Teixobactin is an extract of β-proteobacteria named Eleftheria terrae. This antibiotic is only tested in mice. Clinical trials must be carried out to ensure the drug is safe and works for patients. Human trials have not started, so the drug will not be available for at least 3-4 years.
Time will prove Teixobactin will develop into a new drug or not.
How Teixobactin was discovered?
A new tool, iChip, was used to isolate teixobactin from a soil microorganism, Eleftheria terrae. This microbe does not grow in the test tube in laboratory conditions. This tool or device allows the researchers to dilute the bacteria-containing soil samples. Then, sandwich them between two semi-permeable membranes and immerse them in soil. Thus, allowing the bacteria to grow in the laboratory in natural conditions.
Scientists believe that this screening could be a ‘game changer’ for discovering new antibiotics from environmental sources. This allows compounds to isolate from micro-organisms in the soil that do not grow under normal laboratory conditions.
Uses
Teixobactin is not a panacea against all bacteria. According to the researcher, Teixobactin was ineffective against most Gram-negative bacteria but had shown excellent activity against Gram-positive pathogens, including drug-resistant strains:
- Potency against most species, including difficult-to-treat enterococci and M. tuberculosis
- Teixobactin was exceptionally active against Clostridioides difficile (also known as Clostridium difficile) and Bacillus anthracis.
- Teixobactin had excellent bactericidal activity against S. aureus, MRSA (Methicillin-Resistant Staphylococcus aureus), and Vancomycin Intermediate Staphylococcus aureus (VISA)
Mechanism of Action
Teixobactin is an unusual depsipeptide that contains enduracididine, methylphenylalanine, and four D-amino acids. It inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid).
To Read more: